Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
8(80%)
Results Posted
100%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
3
30%
Ph phase_3
1
10%
Ph phase_2
6
60%

Phase Distribution

3

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

8

trials recruiting

Total Trials

10

all time

Status Distribution
Active(8)
Completed(1)
Terminated(1)

Detailed Status

Recruiting5
Active, not recruiting3
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
8
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)

Trials by Status

terminated110%
active_not_recruiting330%
recruiting550%
completed110%

Recent Activity

8 active trials
Showing 5 of 10
recruitingphase_3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347
recruitingphase_2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
recruitingphase_2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017
recruitingphase_1

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830
recruitingphase_1

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT05139017Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
NCT05562830Phase 1

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Recruiting
NCT06395103Phase 1

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Recruiting
NCT05458297Phase 2

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Active Not Recruiting
NCT05144841Phase 2

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active Not Recruiting
NCT04504916Phase 2

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Terminated
NCT05406401Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active Not Recruiting
NCT03833180Phase 1

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10